PBH Prestige Brand Holdings Inc

Rice Hall James & Associates LLC reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.6% during the third quarter, selling 30,225 shares. The fund now holds 509,668 shares valued at $31.8 million, making PBH its 12th largest holding. Prestige Consumer Healthcare exceeded Q3 EPS estimates and reported $274.1 million in revenue, while institutional investors own 99.95% of the stock.

Zacks Research has issued a bullish forecast for Prestige Consumer Healthcare (NYSE:PBH) Q1 2027 earnings, raising their EPS estimate to $1.24 and maintaining a "Hold" rating. This update comes after Prestige Consumer Healthcare surpassed Q4 expectations with $1.07 EPS and $274.11M in revenue, and set an optimistic FY2026 guidance. Analyst sentiment remains mixed, leading to a "Moderate Buy" consensus.

Assenagon Asset Management S.A. initiated a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during Q3, acquiring 30,286 shares valued at approximately $1.89 million, making it one of several institutions to recently adjust their holdings. The company reported strong Q3 earnings, beating EPS and revenue estimates, and provided positive FY2026 guidance. Despite some recent analyst price target adjustments and a minor insider stock sale, institutional investors hold a significant 99.95% of the stock, with a consensus "Moderate Buy" rating and an average price target of $85.33.

Congress Asset Management Co. significantly cut its stake in Prestige Consumer Healthcare Inc. by 70.7% in Q3 2025, selling 714,172 shares and retaining 295,423 shares valued at approximately $18.43 million. Despite this, Prestige Consumer Healthcare surpassed its Q3 earnings and revenue estimates, and analysts maintain a "Moderate Buy" consensus rating with a target price significantly above the current stock price. Other institutional investors, however, increased their holdings in the company during the same period.

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 1-year price target of $85.33. The company recently reported strong earnings, beating EPS and revenue estimates, and provided positive FY2026 guidance. Insider activity includes a sale by VP Jeffrey Zerillo, while institutional investors hold nearly all of the company's stock.

Prestige Consumer Healthcare (PBH) recently saw a new stake from Brandes Small Cap Value Fund and confirmed share repurchases of about 4.7% since mid-2024. These actions, alongside fiscal 2026 revenue guidance indicating modest organic decline, suggest growing confidence in the company's acquisition-led model and its focus on resilient OTC brands. The article explores how these developments impact PBH's cash-flow-driven investment narrative, noting that the Simply Wall St Community currently values PBH at US$78, a 26% upside to its current price.